Allogene Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
ALLO$1.06+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(135,653) | $(152,076) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 27,735 | 29,512 |
| Depreciation and amortization | 8,100 | 9,302 |
| Net amortization/accretion on investment securities | (3,903) | (3,400) |
| Impairment of long-lived assets | — | 2,382 |
| Non-cash rent expense | 3,246 | 3,308 |
| Non-cash collaboration revenue - related party | (4,640) | — |
| Changes in operating assets and liabilities: | ||
| Deposit placed in escrow | 23,479 | (2,699) |
| Prepaid expenses and other current assets | 671 | 2,252 |
| Other long-term assets | (214) | (1,188) |
| Accounts payable | 4,505 | (1,830) |
| Accrued and other current liabilities | 898 | (2,402) |
| Operating lease liabilities | (6,318) | (5,614) |
| Other long-term liabilities | 1,067 | 806 |
| Net cash used in operating activities | (81,027) | (121,647) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (184) | (386) |
| Proceeds from maturities of investments | 180,627 | 172,212 |
| Purchase of investments | (331,474) | (109,880) |
| Net cash provided by (used in) investing activities | (151,031) | 61,946 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs | 20,668 | 14,495 |
| Proceeds from issuance of common stock from public offering, net of commissions and issuance costs | 187,872 | — |
| Proceeds from CIRM award (Note 5) | — | 6,908 |
| Proceeds from issuance of common stock upon exercise of stock options | 4 | — |
| Proceeds from issuance of common stock under the employee stock purchase plan | 1,096 | 895 |
| Net cash provided by financing activities | 209,640 | 22,298 |
| Net change in cash and cash equivalents and restricted cash | (22,418) | (37,403) |
| Cash and cash equivalents and restricted cash — beginning of period | 61,980 | 85,510 |
| Cash and cash equivalents and restricted cash — end of period | $39,562 | $48,107 |
| Non-cash operating activities: | ||
| Property and equipment purchases in accounts payable and accrued liabilities | $— | $107 |
| Supplemental disclosure: | ||
| Cash paid for amounts included in the measurement of lease liabilities | $(9,822) | $(9,685) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.